Saturday 3 December 2016

Scientists to test ecstasy as an anti-anxiety medicine

Emmett Berg

Published 27/05/2015 | 07:43

Ecstasy - medically known as MDMA
Ecstasy - medically known as MDMA

California scientists are testing whether ecstasy could help alleviate anxiety in terminally ill patients.

  • Go To

At least a dozen subjects with life-threatening diseases like cancer, and who are expected to live at least 9 months, will participate in the double-blind trial over the next year in Santa Cruz, said Brad Burge, spokesman for the Multidisciplinary Association for Psychedelic Studies.

Each subject will be randomly given either a full dose - 125 milligrams of MDMA (ecstasy), or an "active placebo" dose of 30 milligrams, Burge said.

The goal is to test whether gravely ill patients suffering from debilitating anxiety, fear or depression due to their diagnoses can find a measure of peace during the extended ecstasy-influenced psychotherapy sessions.

The trial's principal investigator, Dr. Philip Wolfson, told the San Francisco Chronicle newspaper that the MDMA experience, lasting four or five hours, can be "transformationally potent" under controlled settings with a pair of trained therapists.

"It's a substance that supports deep, meaningful and rapidly effective psychotherapy," Wolfson told the Chronicle.

MDMA (esctasy) is a psychoactive drug that has been banned under federal law for decades.

Results were expected within 12 to 15 months.

"Our hypothesis is that something is happening with MDMA that makes psychotherapy easier," Burge said.

"So with a lower dose of MDMA in the active placebo, it might fool the subject or the therapist. And by giving people the option of following up with another half dose, it just extends the window for therapy rather than making it more intense."

Those receiving the full dose have an option later to take another 62.5 milligram dose as part of the same session, and those receiving the placebo can later re-enter the trial, he said.

Reuters

Read More

Promoted articles

Editors Choice

Also in World News